Rare Kidney Diseases Market Specificity: "Rare Kidney Diseases" clearly defines the market focus 2024-2031

Rare Kidney Diseases Market to is Projected to Grow at a CAGR of 16%, During the Period 2022-2030, claims InsightAce Analytic

InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Rare Kidney Diseases Market By Target Indications (IgA Nephropathy, Membranous Nephropathy, Lupus Nephritis, C3 Glomerulopathy, Focal Segmental Glomerular Sclerosis, and Others), Type of Molecule (Small Molecules and Biologics (Hormone, Monoclonal Antibody, Recombinant Protein, and Others)), Route of Administration (Intravenous, Oral, Subcutaneous, and Others))- Market Outlook and Industry Analysis 2030" According to company's newest research, the global rare kidney diseases market is predicted to exhibit a promising CAGR of 16% between 2024 and 2031.
Get a free sample copy of the report:https://www.insightaceanalytic.com/request-sample/1414

The Silent Threat: Rare Kidney Disorders and the Urgent Need for New Treatments
This passage highlights the significant burden of rare kidney disorders (RKDs). Here's a breakdown with improved paragraph alignment:
Prevalence and Impact:
• RKDs encompass a vast range of over 150 different illnesses.
• Estimates suggest a high prevalence, with 60-80 cases per 100,000 individuals in the US and Europe.
• Common conditions like diabetes and hypertension significantly increase the risk of kidney disease, affecting roughly one-third and one-fifth of adults with these conditions, respectively.
Mortality and Challenges:
• Data indicates that RKDs claim more lives than both breast and prostate cancer combined (based on the 2018 NVS 2021 report).
• Patients with RKDs face a substantially higher risk of death (5-10 times greater) before reaching kidney failure when undergoing replacement therapy (KFRT).
COVID-19 Impact:
• The COVID-19 pandemic severely impacted treatment for RKDs.
• Many RKD treatments require frequent hospital or clinic visits, which became more difficult during the pandemic.
• This resulted in a concerning 30% increase in mortality rates for RKD patients.
Future Direction:
• The rising death rate has spurred the pharmaceutical industry to invest in research and development of new, effective treatments for RKDs.

Several essential factors are driving the growth of the market for rare kidney diseases. The collaborative interactions among clinicians, patients, industry representatives, regulatory agents, and government agencies contribute to the expansion of the need for complex illnesses due to new advancements in diagnosis and treatment. In addition, the increased use of next-generation sequencing techniques is expected to improve diagnostic accuracy for rare kidney diseases, aid in elucidating molecular mechanisms of disease, facilitate genetic counselling, and provide opportunities for carrier testing. Renal replacement therapy advancements and increased accessibility enable patients to live longer lives at the expense of their quality of life.
The market restraining factors include unresolved genetic defects, a lack of biomarkers to track disease progression, heterogeneous clinical phenotypes, and obsolete diagnostic classifications that do not reflect underlying pathophysiological mechanisms, which have hindered therapeutic advances in rare kidney diseases. Slow drug approvals and complex studies will also restrain the market's growth.
North America will dominate and lead the global market for rare kidney diseases during the forecasted period as a result of its rapid clinical advancements and research into kidney disease treatments.
The key market players are GlaxoSmithKline, Recordati Rare Diseases, Amicus Therapeutics, Calliditas Therapeutics, Alexion Pharmaceuticals (A subsidiary of AstraZeneca), Travere Therapeutics, Aurinia Pharmaceutical, Advicenne, Protalix Biotherapeutics, AstraZeneca, Chinook Therapeutics, Reata Pharmaceuticals, Roche, Novartis Pharmaceuticals, Merk & co., Apellis Pharmaceuticals, Omeros Corporation, Lonza, and Other Prominent Players.
Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1414
Key Developments in The Market:
• In Aug 2022, CSL Vifor and Travere Therapeutics announced that the European Medicines Agency (EMA) has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of a rare kidney disorder IgAN, and a leading cause of end-stage kidney disease (ESKD).
• In Dec 2021, The FDA approved the first drug to reduce urine protein levels in IgA nephropathy, a rare kidney disease. Tarpeyo (budesonide) delayed-release capsules have been granted accelerated approval by the FDA to minimise proteinuria (increased protein levels in the urine) in adults with primary immunoglobulin A (IgA) nephropathy who are at risk of rapid disease progression.
• In Sept 2021, Allarity Therapeutics and Lonza agreed to collaborate on developing and manufacturing dovitinib, Allarity's renal cell carcinoma candidate therapy. The agreement called for the start of dovitinib manufacturing in 2022 to meet Allarity's projected needs for bringing dovitinib to market after regulatory approvals.
• In June 2021, Novartis announced new Phase II interim data for iptacopan in the rare kidney disease C3 glomerulopathy (C3G). Iptacopan is being developed for a number of (CDRDs) complement-driven renal diseases, including C3Gand (IgAN) IgA nephropathy, the blood disorder paroxysmal nocturnal hemoglobinuria (PNH), with the goal of addressing a vital driver of these diseases.
Market Segmentation
Global Rare Kidney Diseases Market, by Target Indication, 2022-2030 (Value US$ Mn)
• IgA Nephropathy
• Lupus Nephritis
• Focal Segmental Glomerular Sclerosis
• Membranous Nephropathy
• C3 Glomerulopathy
• Cystinosis
• Dense Deposit Disease
• Distal Renal Tubular Acidosis
• Fabry Disease
• Refractory Gout
• Atypical Hemolytic Uremic Syndrome
• Others

Global Rare Kidney Diseases Market, by Type of Molecule, 2022-2030 (Value US$ Mn)
• Small Molecules
• Biologics
o Monoclonal Antibody
o Hormone
o Recombinant Protein
o Others

Global Rare Kidney Diseases Market, by Route of Administration, 2022-2030 (Value US$ Mn)
• Oral
• Intravenous
• Subcutaneous
• Others

Global Rare Kidney Diseases Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada

Europe Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

For Customization: https://www.insightaceanalytic.com/customisation/1414

Other Related Reports Published by InsightAce Analytic:

Global Biosimilar Monoclonal Antibodies Market
Global Dialysis Equipment Market
Global Therapeutic Proteins and Oral Vaccines Market

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.